Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommaso Clemente

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Viruses|July 30, 2025
Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of SteatosisAlessia Siribelli, Sara Diotallevi, Laura Galli, et al.
The Journal of Infectious Diseases|September 24, 2025
Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIVMehdi Benlarbi, Jonathan Richard, Tommaso Clemente, et al.
The Journal of Antimicrobial Chemotherapy|November 21, 2024
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life settingRebecka Papaioannu Borjesson, Tommaso Clemente, Sara Diotallevi, et al.
International Journal of Antimicrobial Agents|June 21, 2023
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life settingTommaso Clemente, Laura Galli, Andrea Poli, et al.
The Journal of Infection|March 13, 2023
Inflammation burden score in multidrug-resistant HIV-1 infectionTommaso Clemente, Roberta Caccia, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2024
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Domenico Pontillo, Tommaso Clemente, et al.
AIDS (London, England)|November 15, 2023
Sexually transmitted infections in people with multidrug-resistant HIVTommaso Clemente, Riccardo Lolatto, Rebecka Papaioannu Borjesson, et al.
HIV Medicine|April 30, 2026
Effectiveness of switching regimen in people living with HIV and persistent low-level viraemia in the modern antiretroviral treatment eraTommaso Clemente, Pierluigi Reali, Riccardo Lolatto, et al.
Open Forum Infectious Diseases|July 4, 2024
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART StudyCamilla Muccini, Nicola Gianotti, Sara Diotallevi, et al.
Open Forum Infectious Diseases|May 22, 2026
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA CohortAlessandra Vergori, Adriana Cervo, Ashley Roen, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Viruses|July 30, 2025
Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of SteatosisAlessia Siribelli, Sara Diotallevi, Laura Galli, et al.
The Journal of Infectious Diseases|September 24, 2025
Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIVMehdi Benlarbi, Jonathan Richard, Tommaso Clemente, et al.
The Journal of Antimicrobial Chemotherapy|November 21, 2024
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life settingRebecka Papaioannu Borjesson, Tommaso Clemente, Sara Diotallevi, et al.
International Journal of Antimicrobial Agents|June 21, 2023
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life settingTommaso Clemente, Laura Galli, Andrea Poli, et al.
The Journal of Infection|March 13, 2023
Inflammation burden score in multidrug-resistant HIV-1 infectionTommaso Clemente, Roberta Caccia, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 13, 2024
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Domenico Pontillo, Tommaso Clemente, et al.
AIDS (London, England)|November 15, 2023
Sexually transmitted infections in people with multidrug-resistant HIVTommaso Clemente, Riccardo Lolatto, Rebecka Papaioannu Borjesson, et al.
HIV Medicine|April 30, 2026
Effectiveness of switching regimen in people living with HIV and persistent low-level viraemia in the modern antiretroviral treatment eraTommaso Clemente, Pierluigi Reali, Riccardo Lolatto, et al.
Open Forum Infectious Diseases|July 4, 2024
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART StudyCamilla Muccini, Nicola Gianotti, Sara Diotallevi, et al.
Open Forum Infectious Diseases|May 22, 2026
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA CohortAlessandra Vergori, Adriana Cervo, Ashley Roen, et al.
Pageof 4